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Abstract In recent years, natural edible products have been
found to be important therapeutic agents for the treatment of
chronic human diseases including cancer, cardiovascular dis-
ease, and neurodegeneration. Curcumin is a well-known
diarylheptanoid constituent of turmeric which possesses anti-
cancer effects under both pre-clinical and clinical conditions.
Moreover, it is well known that the anticancer effects of
curcumin are primarily due to the activation of apoptotic path-
ways in the cancer cells as well as inhibition of tumor micro-
environments like inflammation, angiogenesis, and tumor me-
tastasis. In particular, extensive studies have demonstrated that
curcumin targets numerous therapeutically important cancer
signaling pathways such as p53, Ras, PI3K, AKT, Wnt-β
catenin, mTOR and so on. Clinical studies also suggested that
either curcumin alone or as combination with other drugs
possess promising anticancer effect in cancer patients without
causing any adverse effects. In this article, we critically review
the available scientific evidence on the molecular targets of
curcumin for the treatment of different types of cancer. In
addition, we also discuss its chemistry, sources, bioavailabil-
ity, and future research directions.
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Introduction
The term cancer is defined as a group of diseases caused by
abnormal cell growth with the potential to invade to different
body organs [1, 2]. Statistically, cancer occurs in 14.1 million
people in the world annually [3, 4]. Awide range of scientific
evidence shows that 90–95 % of cancer cases have been in-
duced by epigenetic factors, with remaining cases due to ge-
netic factors [5–7]. It is well known that tobacco smoking,
diet, infections, radiation, and environmental pollutants are
the most important and common causes of cancer worldwide
[8–10].
Current therapeutic strategies for cancer (such as surgery,
chemotherapy, phototherapy, and radiotherapy) have been as-
sociated with numerous limitations, including drug resistance,
a high risk of relapse, unavailability of treatment, and poor
outcomes. In view of these, recent research has been focused
on the molecular mechanisms at the basis of the uncontrolled
cell proliferation of cancer cells and the presence of genetic
alterations in their cell cycle. Numerous molecular mecha-
nisms have been found to lead to uncontrolled growth of can-
cer cells. For instance, overexpression of cyclin-dependent
kinases (CDK 4, 6, 1, and 2) and underexpression of tumor
suppressor proteins (p53) have been commonly observed in
cancerous tissues [11]. In addition, several cell cycle regula-
tory proteins, such as CDK inhibitors (CKIs) p21, p27, and
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p57, are also deregulated in malignant conditions. Hence,
targeting the key molecules in a cancer cell cycle is an effec-
tive approach in cancer therapy [12]. In addition, over the last
few years, research has been focused on natural anticancer
agents due to their high therapeutic potential and negligible
adverse effects [13–19].
Plants are rich sources of bioactive natural compounds
[20–24] like polyphenolic compounds, which are known as
one of the most important classes of natural products with
multiple therapeutic effects [25–29]. Curcumin (1,7-bis(4-hy-
droxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione) (Fig. 1)
is a naturally occurring polyphenolic phytochemical isolated
from the powdered rhizome of the Curcuma longa L.
(Zingiberaceae) [30]. It was discovered in 1815 by Vogel
and Pelletier as a yellow pigment [31]. This yellow-colored
hydrophobic compound has been traditionally consumed for
over 2000 years in Asian countries due to its various medici-
nal properties against human pathological diseases, such as
cancer and neurodegenerative diseases [32–35]. Moreover,
in the last few decades, more than 10,200 research publica-
tions and 258 clinical studies have been performed on
curcumin and cancer (PubMed report). Numerous molecular
t a r g e t s h a v e b e e n p r o p o s e d c o n c e r n i n g t h e
chemotherapeutical effect of curcumin against different types
of cancer. Extensive studies indicate that it can modulate all
kinds of cancer hallmarks, including uncontrolled cell prolif-
eration, cancer-associated inflammation, cancer cell death,
signaling pathways, cancer angiogenesis, and metastasis
[36]. During the past two decades, several studies have been
reviewed in the literature regarding molecular targets underly-
ing the anticancer effects of curcumin [37–42]. Shehzad et al.
[37] showed that curcumin inhibits several cell signaling pro-
teins such as nuclear factor-kappa B (NF-κB), activator pro-
tein 1 (AP-1), cyclooxygenase-2 (COX-2), matrix metallopro-
teinases (MMPs), cyclin D1, epidermal growth factor receptor
(EGFR), Akt, β-catenin, as well as tumor necrosis factor
(TNF). They also showed that caspase family proteins and
anti-apoptotic genes such as Bcl-2 and Bcl-XL were other
molecular targets of curcumin in the cancer cells. Oyagbemi
et al. [38] showed that curcumin possesses inhibitory effects
against cytochrome P450, as well as COX-2, lipooxygenase,
ornithine decarboxylase (ODC), NF-κB, c-Jun N-terminal ki-
nase, and protein kinase C. In another review by Goel et al.
[39], COX-2, HER2, TNF, EGFR, Bcr-abl, proteosome, and
vascular endothelial cell growth factor are reported as molec-
ular targets of anticancer effects of curcumin. Thangapazham
et al. [40] also showed that anticancer effects of curcumin are
mainly due to its inhibition of the transcription factor NF-κB.
Studies by Shehzad and Lee [41] showed that the chemopre-
vention effects of curcumin are mainly due to regulation of
different molecular pathways in cell signaling, such as NF-κB,
Akt, MAPK, p53, Nrf2, Notch-1, JAK/STAT, β-catenin, and
AMPK. In a recent study carried out by Tuorkey et al. [42], it
has been reported that the anticancer effects of curcumin are
due to modulation of cell cycle, apoptotic signals, anti-
apoptotic proteins, miRNAs, Wnt/beta-catenin signaling, pro-
tein kinases, NF-κB, proteasome activation, epigenetic regu-
lation including DNA methylation and histone modification.
In the present article, we critically review the molecular targets
of curcumin and its benefits as a drug for cancer therapy. We
also discuss its chemistry, sources, bioavailability, and future
research directions.
Metabolism
One of the drawbacks in the use of curcumin as a therapeutic
agent is its rapid metabolism. After adsorption, reduction of
the double bonds in the heptadienedione chain takes place,
leading to the production of a series of active metabolites
[43]. Alcohol dehydrogenase reduces curcumin to tetra- and
hexahydrocurcumin in the liver, and an unidentified micro-
somal enzyme leads to the formation of di- and octa-
hydrocurcumin [30, 31]. Curcumin and the reduced metabo-
lites undergo glucuronidation and are converted into curcumin
glucuronide and curcumin sulfate [30, 31]. A cleavage of
heptadienedione resulting in vanillin, ferulic acid, and
feruloylmethane is also possible; however, it is only a minor
pathway [44].
Bioavailability
Curcumin has very low water solubility (<0.005 % w/v) and a
high oil–water partition coefficient (logP = 3.1), which pre-
sents another problem in its use as a therapeutic agent [45].
The water solubility is low at both acidic and neutral pH;
however, curcumin is soluble at pHs above neutral.
Tønnesen and Karlsen [46] determined the pKa values for
the dissociation of the three acid protons in curcumin to be
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Fig. 1 Chemical structure of curcumin
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7.8, 8.5, and 9.0. The compound undergoes rapid decomposi-
tion in alkaline media, with a half-life in the range of few
minutes. Additionally, photodegradation takes place in organ-
ic solvents. These facts limit the applications of curcumin as a
bioactive agent [47].
Many techniques have been attempted in order to over-
come limitations caused by poor solubility. More than 1500
papers have been published prior to 2015 to find the suitable
techniques to improve the bioavailabitity of curcumin.
Recently, nanoformulation-based approaches have been
attempted. The water solubility of curcumin is significantly
improved when it is present in a complex with cyclodextrins.
This also improves the stability of curcumin under alkaline
conditions but decreases photostability [47]. Stability of
curcumin against alkaline hydrolysis can be improved by en-
capsulation in micelles composed of cationic surfactants like
ce ty l t r imethylammonium bromide and dodecyl
trimethylammonium bromide [47]. Oral administration to rats
of a phospholipid complex of curcumin significantly increases
bioavailability (maximum plasma drug concentration improv-
ing from 266.70 ng/ml with Tmax = 1.62 h to 600.93 ng/ml
with Tmax = 2.33 h) [48], as the curcumin-phospholipid com-
plex has better solubility and absorption. It also acts better as
an antioxidant and thus has improved effects, such as better
hepatoprotective activity [49]. Emulsion-based delivery sys-
tems are one of the vehicles that are being increasingly used to
protect active ingredients against extreme conditions, to en-
hance their stability, and to deliver lipophilic bioactive com-
pounds in order to increase bioavailability [44, 50]. Ahmed
et al. [44] designed a study, where in vitro digestion model
was used to evaluate the influence of oil droplet size and lipid
phase composition to measure lipid digestion. This model was
used to investigate curcumin bioaccessibility. A 0.15 % w/v
curcumin in the lipid phase was used to prepare either emul-
sions or nanoemulsions. Long, medium, and short chain triac-
ylglycerols were used as a lipid phase. Results demonstrated
that the bioaccessibility of curcumin is highest when medium
chain triacylglycerols are used and is slightly better in conven-
tional emulsions than in nanoemulsions.
In the mouse ear inflammationmodel, it was shown that the
anti-inflammatory activity is strongly dependent on the size of
droplets of oil-in-water (o/w) nanoemulsions [50]. In the range
of 618.6 to 79.5 nm of 1 % curcumin, there was a 43 or 85 %
inhibition effect, respectively. Yu and Huang [51] managed to
encapsulate curcumin in hydrophobically modified starch, in-
creasing solubility to about 1670-fold. A nanoemulsion com-
posed of 20% soybean oil, 10% Tween 80, and 20% glycerol
was used to encapsulate 0.07 % of curcumin. After 60 days,
70% of the initial amount of curcumin was found to remain in
the resulting nanoemulsion [52]. Li et al. [53] used a simple
solution mixing method in order to disperse curcumin in the
matrix of a cationic polyelectrolyte EUDRAGIT® E PO com-
posed of dimethylaminoethyl methacrylate, butyl
methacrylate, and methyl methacrylate with a molar ratio of
2:1:1. In this way, the water solubility of curcumin was sig-
nificantly increased to at least 3 mg/ml which is similar to that
in conventional organic solvents. Curcumin was also effec-
tively protected from hydrolysis under all pH values examined
(5–8), as well as from ultraviolet (UV) degradation. Curcumin
loaded into mixed polymeric micelles showed significant im-
provement in oral bioavailability (around 55-fold) compared
to curcumin alone [54].
Molecular targets of curcumin for cancer therapy
Effect of curcumin on CDK/cyclin complexes and CDK
inhibitors
CDKs are serine/threonine kinases that control cell cycle pro-
gression by forming a complex with their respective cyclin
partner [55]. In malignant cells, altered expressions of
CDKs, over-expression of cyclins, and loss of expression of
CDK inhibitors have been commonly observed. The
deregulated CDK activity provides a selective growth advan-
tage for cancer cells. Several studies have documented that
curcumin targets the CDK activity and represses the tumor
progression. A recent study suggests that curcumin directly
targets the overexpression of CDK2 protein function in colon
cancer cells [56]. In vitro data reveals that curcumin inhibits
the proliferation of HCT116 colon cancer cells by causing G1
cell cycle arrest and reduces expression of phosphorylation of
retinoblastoma (Rb) protein. Ex vivo results show that
curcumin has a strong affinity for the adenosine triphosphate
(ATP) pocket of CDK2 protein. Moreover, curcumin shows
reduced anticancer potential on CDK2 knockout HCT116 co-
lon cancer cells [56]. This study clearly depicts that curcumin
could be a potent cell cycle modulatory agent against CDK2
overexpressed colon cancer cells. In addition, curcumin also
promotes the expression of several cyclin-dependent kinase
inhibitors (CKIs), including p21, p27, and ING4, in tumor
cells. For instance, curcumin-treated prostate cancer cells
show apoptosis induction and G1/S phase arrest. The molec-
ular mechanism has been revealed as an increased expression
of CDK inhibitors, such as CDK inhibitor 2A (p16/INK4a),
CDK inhibitor 1 (p21/WAF1/CIP1) and CDK inhibitor 1B
(p27/KIP1) and an inhibition of the expression of cyclin E
and cyclin D1, and hyperphosphorylation of Rb protein [57].
It was further confirmed by proteosome inhibitor lactacystin,
which inhibits curcumin-induced suppression of both cyclin E
and cyclin D1. Besides, curcumin-induced apoptosis is
inhibited upon addition of p21-specific siRNA. Furthermore,
curcumin-treated U-87MG human glioblastoma cells show
reduced cell proliferation and higher expression of
p21WAF1/CIP1. Choi and colleagues [58] investigated a nov-
el mechanism of curcumin-induced p21WAF1/CIP1
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expression in U-87MG human glioblastoma cells. Early
growth response protein 1 (Egr-1) is a nuclear protein which
performs a wide range of functions involved in transcriptional
regulation, tumor suppression, cell differentiation, and
mitogenesis [59, 60]. Curcumin induces the expression of
Egr-1 through extracellular signal-regulated kinase (ERK)
and c-Jun NH2-terminal kinase (JNK), but this effect is abro-
gated on addition of Egr-1-specific small interfering RNA
(siRNA) and knock-downed Egr-1U-87MG cells [58]. In
summary, these studies confirm that curcumin could be a se-
lective anticancer drug for cancer chemotherapy.
Cyclin E is a nuclear protein which plays an important role
in G1/S progression by interacting with their catalytic partner,
the CDK2, and Rb [61].Moreover, the deregulated expression
of cyclin E has also been correlated with malignant transfor-
mation of various tumor cells including breast, head and neck,
prostate, lung, and leukemic cell lines [62]. Curcumin-treated
MCF-7 breast cancer cells showed reduced cell proliferation
and arrested growth at the G1 phase. The growth inhibitory
mechanism of curcumin has been revealed as downregulation
of cyclin E by promoting proteosomal degradation and upreg-
ulation of the CDK inhibitors p53, p21, and p27. Additionally,
the effect is suppressed, and cyclin E is upregulated by addi-
tion of specific proteosomal inhibitors. Overall, the study sug-
gests that proteasome-mediated downregulation of cyclin E
and upregulation of CDK inhibitors may contribute to the
antiproliferative effects of curcumin [63]. Similarly, curcumin
causes G1/S block in human osteosarcoma cells. Both flow
cytometry and Western blot analysis show that reduction of
expression pattern of cdc2/cyclin B complex formation is an
essential step in the entry of the cell to S phase [64]. In addi-
tion, curcumin-treated ECV304 human umbilical vein endo-
thelial cells induce G0/G1 and/or G2/M phase cell cycle arrest.
Microarray analysis results show increased expression of
CDKIs, p21WAF1/CIP1, p27KIP1, and p53 and downregula-
tion of cyclin B1 and CDC2 in ECV304 cells [65].
Furthermore, curcumin selectively targets CDK2
overexpressed cancer cells without affecting the normal cells.
The study suggests that curcumin induces the p53-dependent
apoptosis and causes G2 phase arrest in mammary carcinoma
cells. In contrast, this effect is different in curcumin-treated
normal human mammary cells. It causes G0 cell cycle arrest
by blocking the association of Cdk4/Cdk6, as well as by
inhibiting phosphorylation of retinoblastoma and preventing
the entry of p53-mediated apoptosis. The p53-mediated apo-
ptosis occurs only in G2 phase-arrested cells [66].
Inhibitor of growth protein 4 (ING4) is a tumor suppressor
protein involved in cell cycle arrest and apoptosis induction in
the case of DNA damage [67]. Suppressed expression of
ING4 protein is observed in numerous cancer tissues and
transformed cancer cell lines [68]. In addition, increased ex-
pression of pro-inflammatory mediators has been correlated
with suppressed expression of ING4 in human brain tumor
cells. Curcumin-treated human glioma cells U251 show re-
duced cell proliferation and G2/M phase of cell cycle arrest.
Moreover, Western blot analysis shows that curcumin-treated
cells exhibit increased expression of p53, p21, and ING4 in a
dose-dependent manner. It suggests that curcumin upregulates
the expression of p21 and p53 through ING4, which negative-
ly impairs the growth of human glioma cells [69]. These
promising facts show that curcumin could be a potent cell
cycle modulator in cancer cells.
Effect of curcumin on p53 pathway
p53 is one of the most important tumor suppressor proteins,
governing a wide range of cellular processes, including cell
proliferation, DNA damage, apoptosis, and so on. p53 is
encoded by the TP53 gene which is often mutated in many
types of human cancers [70]. This mutation leads to the loss of
wild-type activity of p53 which results in loss of cell prolifer-
ative control, DNA check points, DNA repair mechanisms,
cell death and so on. These characteristic features support
the immortal properties of cancer cells. Hence, recovery of
the function of p53 is an attractive therapeutic opportunity in
cancer therapy [71]. Curcumin induces apoptosis in various
cancer cells by p53-dependent and p53-independent path-
ways. For instance, curcumin-treated breast cancer cells
(MCF-7) showed cell cycle arrest and p53-dependent apopto-
sis. Furthermore, the chemopreventive mechanism of curcumin
reveals that curcumin has no effect on null p53 MDAH041
cells and low p53-expressing TR9 cells. Conversely, its effect
is higher in p53 expressing cells, such as TR-7 and MCF-7. In
addition, the expression of pro-apoptotic protein Bax is also
higher in curcumin-treated MCF-7 cells. Altogether, these re-
sults suggest that curcuminmediates its chemopreventive prop-
erty through a p53-dependent pathway [72].
Targeting the DNA to promote wild-type p53 function in
cancer cells is an attractive strategy in cancer drug develop-
ment. An earlier study demonstrated that curcumin induces
apoptosis in basal cell carcinoma (BCC) cells, accompanied
by an increase in p53, p21CIP1/WAF1, and DNA damage-
inducible 45 (Gadd45) protein levels. Notably, curcumin
causes apoptotic cell death in BCC cells without causing cell
cycle blockage. These responses are due to p53-DNA binding
activity as well as the expression of two p53 downstream
targets, p21CIP1/WAF1 and Gadd45, in BCC cells after
curcumin treatment. This study concludes that curcumin could
be an effective drug for the therapy or prevention of skin
cancer [73]. Similar results have been reported for S6 myeloid
leukemia cells and HepG2 hepatoma cells, where the induc-
tion of wild-type p53 fails to arrest cell growth during apopto-
sis [74]. In addition, curcumin promotes p53-independent ap-
optosis in HT-29 colon cancer cells by generating superoxide
anions. The effect of curcumin-mediated apoptosis is indepen-
dent of the status of p53. For instance, the apoptotic effect is
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similar in p53 (+/+) and p53 (−/−) HCT-116 cells. It is clear
that the effect of curcumin on colon cancer cells is a p53-
independent mechanism [75].
Targets of curcumin on cancer signaling pathway
Cell signaling pathways are interconnected with each other
and perform a wide range of functions in the human body.
These signalingmechanisms are evolutionary, well controlled,
and occur only when needed, unless they are suppressed by
anti-growth signals. In contrast, cancer cells are self-sufficient;
they do not need any external signals or stimuli for their
growth and function. Altered expression of signaling proteins
has often been reported for controlled proliferation of cancer
cells. For example, proteins, such as Ras, phosphoinositide 3-
kinase (PI3K), EGFR, mammalian target of rapamycin
(mTOR), Akt, NF-κB, Wingless and INT-1 (Wnt), and
mitogen-activated protein kinases (MAPK), are commonly
deregulated in cancerous tissues. Hence, targeting key mole-
cules in cancer signaling pathways may provide a therapeutic
outcome in cancer therapy [76].
Effect of curcumin in Ras signaling
Ras is a small transmembrane protein belonging to the family
of GTPase (a huge family of hydrolase enzymes that hydro-
lyze guanosine triphosphate), a family involved in many cel-
lular functions by transducing signals inside the cell.
Mammalian cells have three distinct Ras proteins, namely
K-, H-, and N-Ras, each playing a different function. Ras is
a well-known oncoprotein, which is constitutively active in
several tumor cells. For instance, K-Ras mutation is frequently
observed in NSCLC tumors, H-Ras is common in bladder and
thyroid cancer, and N-Ras is common in melanoma cancer
cells [77]. Blocking the oncogenic Ras signaling is an attrac-
tive strategy in cancer therapy. Curcumin has been extensively
studied for its role in Ras oncogenic signaling pathways. For
instance, curcumin-treated gastric cancer cells showG2/M cell
cycle arrest, accompanied by decreased expression of cyclin
D1 and increased expression of cyclin B. Moreover, the mo-
lecular mechanism of curcumin leads to the downregulation of
Ras protein and upregulation of ERK. Overall, the study sug-
gested that curcumin inhibits the proliferation of AGS gastric
cancer cells by abolishing the RAS-ERK signaling mecha-
nism [78]. A similar kind of mechanism has been proposed
in Ras-transfected HAG-1 human adenocarcinoma cells. In
brief, the curcumin-treated HAG-1 cells (Ras overexpressed)
showed G2/M cell cycle arrest through predominant expres-
sion of Erk1/2 and Bax and reduced expression of Bcl-xL.
The study suggested that curcumin could be a potent thera-
peutic agent against Ras-overexpressed cancer conditions
[79]. In addition, curcumin treated H-Ras transformed
MCF10A human breast epithelial cells induce reactive
oxygen species (ROS)-mediated downregulation of matrix
metalloproteinase-2 (MMP-2) and B cell lymphoma 2 (Bcl-
2) expression and upregulation of Bax and caspase-3 [80]. A
further in vivo study also suggested that curcumin inhibits two
oncogenes, such as ras-p21 and c-fos, in 7,12-dimethylbenz
(a) anthracene (DMBA) and 12-O-tetradecanoylphorbol-13-
acetate (TPA) induced skin cancer in Swiss albino mice [81].
Overall, these studies confirm that curcumin plays a therapeu-
tic role in the Ras oncogenic pathway. Animal studies and
clinical experiments are needed to clarify the therapeutic effect
of curcumin in Ras-induced cancer systems.
Effect of curcumin in PI3K/AKT/mTOR signaling
PI3Ks are family of lipid kinases which phosphorylate inositol
phospholipids and generate the secondary messenger phos-
phatidylinositol-3,4,5-trisphosphate in the plasma membrane.
PI3K can interact with AKT molecules causing translocation
of AKT inside the cytoplasm. Activated AKT performs nu-
merous functions in cell survival, cell cycle progression, and
cellular growth by interacting with many substrates [82]. The
above mechanisms occur during external stimuli or signals;
otherwise, these pathways are strictly antagonized by various
factors such as phosphatase and tensin homolog (PTEN),
serine/threonine protein kinase beta (GSK3β) and (HB9)
[83]. Moreover, constituted expression of PI3K/AKT and si-
lenced functions of PTEN and GSK3β have been commonly
observed in many human malignant conditions. Hence,
PI3K/AKT is an attractive target in cancer chemotherapy
[84]. Curcumin has been shown to inhibit the PI3K/AKT sig-
nal transduction pathway in several tumor models. For in-
stance, curcumin enhances radiation-induced apoptosis in
three human Burkitt’s lymphoma cell lines by inhibiting the
radiation-induced activation of the PI3K/AKT pathway.
Furthermore, it also downregulates the expression of NF-κB
protein, which is one of the downstream targets for the
PI3K/AKT pathway. In addition, the efficiency of curcumin
is also confirmed by using PI3K- and AKT-specific inhibitors,
such as LY294002 for PI3K or SH-5 for AKT. The activity of
curcumin is equivalent to these known inhibitors, and the
combined effect of curcumin and radiation does not produce
any synergetic effect on human Burkitt’s lymphoma cells [85].
In another study, Yu et al. [86] observed the inhibitory effect of
curcumin-against activated Akt/mTOR signaling in PC-3
prostate cancer cells. Moreover, the activity of curcumin was
similar in siRNA and gene knockout AKT cells, which con-
firms that AKT is not a direct target for its anticancer proper-
ties. Additionally, curcumin also recruits the AMPK and
MAPKs, but inhibition of these kinase enzymes also shows
similar activity in curcumin-treated PC-3 cells. However, un-
der the addition of protein phosphatase (a kinase enzyme
which removes the phosphate group from a protein) inhibitor
calyculin A, the anticancer property of curcumin was
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abrogated. Finally, the study concluded that curcumin inhibits
Akt/mTOR signaling in PC-3 cells by directly targeting PP2A
enzyme [86].
Cancer cells survive for a prolonged time by overexpress-
ing survival (PI3K/Akt/mTOR) and anti-apoptotic pathways
(Bcl-2). It was found that targeting both survival and apoptosis
pathways will be a key strategy in breast cancer therapy in
highly metastatic breast cancer cells. The apoptotic potential
of curcumin is low in breast cancer cells, but the addition of
PI3K-specific inhibitor LY294002 showed increased apopto-
tic potential. The study hypothesized that the blockade of the
PI3K signaling pathway in breast cancer cells by curcumin
overcomes the oncogenic expression of Bcl-2 protein [87].
Collectively, these studies suggest that curcumin could be a
potent PI3K/AKT/mTOR inhibitor in malignant cells; howev-
er, more clinical studies are needed to demonstrate the efficacy
of curcumin for cancer therapy.
Effect of curcumin on Wnt/β-catenin signaling pathway
Wnts is a family of secreted glycoproteins that regulate the
multiple signaling pathways through β-catenin-dependent
and -independent mechanisms. It plays a crucial role in the
development, survival, and fate of cell metabolism.
Inappropriate regulation and hyperactivation of Wnt/β-
catenin signaling have been implicated in numerous human
malignancies. β-Catenin is a key player in this pathway, act-
ing as a signal transducer for several Wnt-targeted genes.
Overexpression of β-catenin leads to constitutive activation
of cell proliferation [88]. On the other hand, GSK3β is a
tumor suppressor protein which controls the activity of β-
catenin through ubiquitin-mediated proteosomal degradation.
However, its expression is suppressed in tumor cells [89].
Therefore, targeting the Wnt/β-catenin signaling pathway is
an attractive approach in cancer therapy. Curcumin causes cell
cycle arrest of G2/M cells in a human medulloblastoma cell
line by modulating the Wnt/β-catenin signaling pathway. The
expression pattern of curcumin-treated medulloblastoma cell
line shows increased expression of tumor suppressor protein
GSK3β and the loss of nuclear β-catenin protein. In addition,
the loss of nuclear β-catenin protein leads to the loss of its
downstream target cyclin D1. Overall, it seems that the anti-
tumor mechanism of curcumin in human medulloblastoma
cells could be due to abrogation of Wnt/β-catenin signaling
[90].
Osteosarcoma is common in young people with aggressive
metastatic potential and poor prognosis rates. The role of
curcumin and its analogs was demonstrated in osteosarcoma
cells. A total of 43 curcumin analogs were screened, of which
six showed 60-fold more potent activity than curcumin in
inhibiting Wnt activity. Moreover, curcumin analogs
disrupted the β-catenin protein nuclear translocation in
osterosarcoma cells. These results suggest that synthesized
curcumin analogs may be more potent than natural curcumin
and that these analogs need to be tested in various Wnt-
overexpressed cells and in animal models [91]. 12-O-
tetradecanoylphorbol-13-acetate (TPA) is a tumor promoter
which acts by activating protein kinase (PKC) and altering
cell signaling pathways [91]. Curcumin inhibits the prolifera-
tion and migration of Hep3B hepatocarcinoma cells by acti-
vating the GSK3β protein and inhibiting the β-catenin func-
tion. Moreover, curcumin also inhibits the TPA-induced Wnt
signaling pathway in xenograft mice model [92]. Overall,
curcumin and its analogs could be potent modulators of
Wnt/β-catenin signaling pathway, and this should be further
validated in human cancer patients.
Target of curcumin on cancer transcription factors
Transcription factors are proteins which play a crucial role in
controlling the expression of several genes. Many of these
transcription factors are tightly regulated and inactive under
normal physiological conditions. Deregulated expression of
several transcription factors have been identified in numerous
cancer tissues. Both activation and inactivation of transcrip-
tion factors can promote cancer development, cell survival,
cell proliferation, and tumor angiogenesis. Libermann and
Zerbini [93] suggest three important families of transcription
factors that play key roles in tumor development, which are
validated for drug discovery. They are NF-κB and AP-1 fam-
ilies, signal transducers and activators of transcription (STAT)
family members and steroid receptors.
Effect of curcumin in NF-κB and AP-1 families
of transcription factors
NF-κB is a family of transcription factors which are involved
in immune response and inflammation. A growing body of
evidence suggests that it is also involved in human cancer. In
cancerous conditions, aberrant and hyperactivated NF-κB has
been observed. NF-κB has been considered as an emerging
target in cancer chemotherapy, and many drugs have been
screened against NF-κB protein function [94]. Curcumin
blocks the HPV16-induced viral oncogenesis in an oral cancer
cell line. The preventive mechanism of curcumin is that it
blocks the DNA-binding capacity of NF-κB by altering its
subunits from p50/p50 to p50/p65. Western blot analysis con-
firmed the downregulation of the protein expression of AP-1
members: c-Jun, JunD, and JunB, along with NF-κB mem-
bers, namely p50 and p65. This study confirms that curcumin
has therapeutic potential for the suppression of HPV16-
mediated oral oncogenesis by blocking the NF-κB and AP-1
families of transcription factors [95]. In another study, Singh
and Aggarwal [96] demonstrated that curcumin inhibited the
NF-κB/AP-1 pathway in chemically induced conditions.
Tumor necrosis factor (TNF), phorbol ester-, and hydrogen
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peroxide rapidly promote the NF-κB function in human my-
eloid ML-1a cells, an effect which is abrogated during
curcumin treatment. It also downregulates NF-κB-mediated
AP-1 function [96]. Likewise, the selective inhibition of
NF-κB by curcumin has also been demonstrated using novel
mouse melanoma cells. The study utilized two different mel-
anoma cells, normal human melanocytes and cells which con-
stitutively expressed NF-κB. Curcumin-treated melanoma
cells showed apoptosis induction by caspase-3 activation
and dose-dependent inhibition of NF-κB activity and down-
stream effect of its target genes, such as COX-2 and cyclin D1.
However, curcumin did not produce any apoptotic effect in
normal human melanocytes [97].
On the other hand, curcumin showed a differential effect in
curcumin-sensitive and -resistant liver cancer cell line. The
curcumin-sensitive hepatoma cells showed inhibition of
NF-κB and downstream signaling, such as JNK, cyclin D1,
and STAT3, but conversely, the curcumin-resistant hepatoma
cells retained their NF-κB function and tumorigenicity even at
a higher concentration of curcumin. The resistance mecha-
nism of curcumin-treated liver cancer cells showed overex-
pression of histone deacetylases (HDAC) protein. Co-
administration of HDAC inhibitor trichostatine reverts the
curcumin-resistant cells into sensitive cells. This study sug-
gests that the combination of curcumin and HDAC inhibitor
could be a novel therapy in treatment of liver cancer [98].
Effect of curcumin in STAT family of transcription factors
STAT is a cytoplasmic transcription factor which plays a vital
role in inflammation and the immune system. It is activated by
phosphorylation through receptor-associated tyrosine kinases
and non-receptor protein kinases. The phosphorylated STAT
forms homo- or hetero-dimerization, migrates into the nucle-
us, and controls gene expression [99]. In cancer cells, STAT is
consistently activated and contributes to the development and
survival of the cells [100, 101]. However, studies have dem-
onstrated that inhibition of STAT function causes growth ar-
rest in several cancer cell lines, which suggests that disruption
of STAT is a promising target in cancer therapy. Curcumin has
been shown to suppress STAT expression in K562 cells. Low
levels of nuclear STAT3 and the truncated forms of STAT-5a
and 5b isoformswere also observed, which suggests the cleav-
age of STAT5 protein under exposure to curcumin.
Additionally, curcumin also downregulates Janus Kinase 2
(JAK2)mRNA expression as well as cyclin D1 and v-src gene
expression in K562 chronic leukemia cells under interferon γ
(IFN-γ) induced conditions. It is clear that curcumin could be
used as a potent therapeutic drug against leukemia [102].
STAT is key factor in many inflammation-mediated cancers,
including ovarian and endometrial malignancies. Curcumin
causes decreased cell viability and increased cleavage of
caspase-3 in ovarian and endometrial cancer cells. This
mechanism of action has been revealed to be reversible inhi-
bition of phosphorylation of STAT-3 and decreased expression
of suppressors of cytokine signaling proteins (SOCS-1 and
SOCS-3). Moreover, on removal of curcumin after 24 h of
treatment, phosphorylated STAT-3 levels returned to normal.
In addition, protein inhibitor of activated STAT (PIAS-3), a
protein involved in the negative regulation of STAT-3 function
and suppressive effect of PIA-3, has been observed in endo-
metrial cancer cells. Curcumin-exposed endometric cells
show upregulation of PIA-3 function. Overall, the report con-
cluded that curcumin exhibits its antineoplastic effects on
ovarian and endometrial cancer cells by suppressing JAK-
STAT signaling mechanisms via activation of PIAS-3, thus
leading to the attenuation of STAT-3 phosphorylation and tu-
mor cell growth [103]. Collectively, the above reports clearly
show that curcumin could be a potent inhibitor of STAT func-
tion in cancer therapy.
Target of curcumin in tumor angiogenesis and metastasis
Angiogenesis is the normal physiological mechanism through
which new blood vessels are formed from preexisting blood
vessels. It occurs during embryogenesis, menstruation, and
wound healing. The role of angiogenesis in tumor has been
extensively studied. Tumor cells procure nutrients for their
uncontrolled growth through the tumor angiogenesis process.
Tumor cells are capable of forming new blood vessels by
constitutively producing pro-angiogenic factors, such as the
VEGF and basic fibroblast growth factor. In the mammalian
system, angiogenesis is strictly controlled by anti-angiogenic
molecules. Several reports suggest that curcumin is able to
modulate the tumor angiogenesis process by inhibiting angio-
genic stimulators [104].
Curcumin inhibits the tumor growth and angiogenesis in
breast cancer cell implanted nude mice. Downregulated ex-
pression of several VEGF isomers such as VEGF-A, VEGF-
C, and VEGFR2 and decreased levels of micro-vessel density
are observed during curcumin treatment. The suppression of
VEGF function leads to the inhibition of breast tumor growth
[105]. Furthermore, a study by Chakraborty et al. [106]
showed the anti-angiogenic potential of curcumin in chemi-
cally induced tumor angiogenic conditions. Osteopontin
(OPN) (a secreted phosphoprotein 1) was able to induce
VEGF function through a NF-κB/ATF-4-dependent pathway.
Curcumin inhibits the tumor growth of MDA-MB-231 cells
(OPN-induced cells) implanted nude mice by abrogating the
binding activity of NF-κB/ATF-4 and inhibiting the VEGF
expression. This clearly suggests that curcumin acts as a po-
tent anti-angiogenic agent in regulating OPN-induced tumor
angiogenesis in breast cancer [106]. Similarly, curcumin and
its analog tetrahydrocurcumin inhibit the tumor growth of
HepG2-implanted nude mice by inhibiting the expression of
COX-2, VEGF, and matrix metalloproteinase-9 (MMP-9)
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[107]. Basic fibroblast growth factor (bFGF) is another potent
angiogenic molecule which stimulates both neovasculariza-
tion and migration of cancer cells. Curcumin inhibits the neo-
vascularization process of angiogenesis in mouse cornea un-
der bFGF induced conditions. In addition, curcumin has no
effect on VEGF expression in transformed human
keratinocyte HaCaT cells under TPA induced conditions. It
is suggested that curcumin has a direct effect on angiogenesis
inhibition, which is relatively specific to endothelial cells and
has little effect on tumor cells [108, 109].
Tumor metastasis is a complex cascade and is the final
event in the carcinogenesis process. Tumor cells actively mi-
grate from their origin into nearby or distinct organs and ulti-
mately lead to death in cancer patients. This metastasis cas-
cade develops due to specific genetic and epigenetic alteration
in tumor cells. Those alterations are degradations of the extra-
cellular matrix (ECM) by MMP, aberrant expression of che-
mokine receptors, tumor inflammation, angiogenesis, and so
on. Hence, inhibition of tumor migration will be a strong
therapeutic approach in metastatic tumor therapy [110, 111].
Several studies have shown signs of promise in using
curcumin as a possible means of treating cancer metas-
tasis. For instance, curcumin inhibits the migration of
colon cancer cells by inhibiting the activity of MMP-9
and suppressing NF-κB and AP-1 activation [111]. A
similar study showed that curcumin inhibits the MMP-
9 activity in TPA-induced human astroglioma U87MG
and U373MG cells by blocking the PKC/MAPK signal-
ing pathways [112]. Recently, Radhakrishnan et al.
[113] reported a novel mechanism of curcumin on the
migration property of colon cancer cells. The study
demonstrated that overexpression of the phosphorylated
form of cortactin protein (especially in phospho tyrosine
421) is attributed to the migration and motility of colon
cancer cells. The tyrosine-protein phosphatase non-
receptor type 1 (PTPN1) is the tyrosine phosphatase
which controls the phosphorylation status of cortactin
protein and negatively regulates its function. However,
in HCT116 cells and SW480 colon cancer cells, the
complete suppression of PTPN1 was observed.
Curcumin-treated HCT116 and SW480 cells show de-
creased levels of pTyr421-CTTN (CTTN is the gene
which encode the cortactin protein) and upregulation
of PTPN1 protein. Moreover, the study concludes that
curcumin interacts with and activates PTPN1 function,
which leads to the dephosphorylation of pTyr421-CTTN
and blocks the migration and motility of colon cancer
cells. This could be exploited for novel therapeutic ap-
proaches in colon cancer therapy based on tumor
pTyr421-CTTN expression [113]. In prostate tumor
cells, migration has been attributed to the presence of
an inflammatory environment. Curcumin inhibits pros-
tate cell migration by abolishing the pro-inflammatory
cytokine CXCL1 and −2 in an orthotopic mouse model
[114]. These observations suggest that curcumin might
target the proteins involved in the metastatic process
and could be used as an effective drug for the treatment
of metastatic oncologic diseases.
Fig. 2 Molecular targets of
curcumin for cancer therapy
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Conclusion
Overall, the accumulated data suggests that the anticancer
effects of curcumin are multi-targeted in nature (Fig. 2). It
can modulate all kinds of cancer hallmarks, including cell
proliferation, cancer signaling pathways, transcription factors,
tumor angiogenesis, and metastasis. In cell proliferation, it
targets the overexpression of CDK2 activity by arresting the
cell cycle. Moreover, several studies suggest that curcumin is
a potent inducer of cyclin-dependent kinase inhibitors, such as
p21WAF1/CIP1, p27KIP1. Additionally, it promotes p53
function in numerous wild and mutant p53 cancer cell lines.
Curcumin also modulates several oncoproteins which are in-
volved in tumor signaling pathways. Notably, curcumin re-
presses the growth of numerous cancer cell lines by targeting
PI3K, AKT, Ras, and β-catenin pathways. Moreover,
curcumin also inhibits several key molecules of tumor angio-
genesis and metastasis including VEGF, MMP, PTPN, and
CXCL1. Collectively, curcumin could be used as an excellent
dietary molecule for the treatment of different types of human
cancer. Finally, we recommended that future studies should be
focused on:
– Increasing the bioavailability of curcumin by liposomal
curcumin, curcumin nanoparticles, curcumin phospholip-
id complex, and so on.
– Ascertaining the most effective formulation of curcumin
for cancer therapy.
– Examination of possible interactions of curcumin with
common anticancer drugs.
– Clinical studies to examine the in vivo anticancer effects
of curcumin.
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